RxDoctor Payments Data

Anu Swarup, MD

Internal Medicine · Mission, TXNPI 1588622021

Payments from drug & device makers

$1,453in general payments, 2019–2025

Across 66 payments — averaging $22.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$404
  • AbbVie$201
  • AstraZeneca$144
  • Bard Peripheral Vascular, Inc.$134
  • Lilly USA, LLC$126
  • Astellas Pharma US Inc$124
  • plus $322 from 10 others

What the payments were for

  • Food & beverage$1,34192%
  • Education$1138%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,453 in reported general payments places this provider in the 70th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$68,298
Medicare patients
197
Services billed
1,895

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin157$161,789
FarxigaDapagliflozin Propanediol135$115,881
OzempicSemaglutide99$102,624
JanuviaSitagliptin Phosphate54$75,736
EliquisApixaban58$68,452
TrulicityDulaglutide44$55,259
MounjaroTirzepatide39$45,461
XareltoRivaroxaban40$45,428
MyrbetriqMirabegron54$41,377
ProliaDenosumab24$40,536
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$35,705
RybelsusSemaglutide14$34,425
KerendiaFinerenone36$28,192
LinzessLinaclotide38$24,085
EntrestoSacubitril/Valsartan20$23,708

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$14$182,107181 claims
Novo NordiskOzempic, Rybelsus, Levemir$404$140,605134 claims
AstraZenecaFarxiga$144$115,881135 claims
Lilly USA, LLCTrulicity, Mounjaro$126$100,72083 claims
PfizerEliquis$16$68,45258 claims
GSKTrelegy Ellipta, Breo Ellipta$12$55,19155 claims
Johnson & JohnsonXarelto$86$45,42840 claims
Astellas Pharma US IncMyrbetriq$124$41,37754 claims
AmgenProlia$42$40,53624 claims
AbbVieLinzess, Lumigan$201$27,56350 claims
NovartisEntresto$35$23,70820 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Mission

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →